Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Rating of “Moderate Buy” from Analysts

Genmab A/S Sponsored ADR (NASDAQ:GMAB) has been assigned an average rating of “Moderate Buy” from the thirteen analysts that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, eight have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $39.17.

A number of analysts have weighed in on the stock. Wall Street Zen cut shares of Genmab A/S from a “buy” rating to a “hold” rating in a report on Saturday, June 14th. Truist Financial reduced their price target on shares of Genmab A/S from $50.00 to $45.00 and set a “buy” rating for the company in a research report on Tuesday, March 11th. HC Wainwright reaffirmed a “buy” rating and set a $37.00 price objective (down previously from $50.00) on shares of Genmab A/S in a report on Wednesday, April 9th. Sanford C. Bernstein cut Genmab A/S from a “market perform” rating to an “underperform” rating in a research report on Tuesday, April 1st. Finally, William Blair raised Genmab A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 11th.

Genmab A/S Price Performance

NASDAQ:GMAB opened at $21.56 on Friday. Genmab A/S has a 12 month low of $17.24 and a 12 month high of $28.56. The firm has a market capitalization of $13.82 billion, a PE ratio of 12.25, a price-to-earnings-growth ratio of 7.11 and a beta of 0.96. The business’s fifty day moving average price is $20.84 and its 200 day moving average price is $20.76.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings data on Thursday, May 8th. The company reported $0.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.08. Genmab A/S had a return on equity of 18.08% and a net margin of 35.11%. The business had revenue of $715.00 million during the quarter, compared to analysts’ expectations of $5.17 billion. As a group, equities analysts anticipate that Genmab A/S will post 1.45 EPS for the current year.

Hedge Funds Weigh In On Genmab A/S

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Rhumbline Advisers lifted its position in Genmab A/S by 3.2% during the 1st quarter. Rhumbline Advisers now owns 16,956 shares of the company’s stock worth $332,000 after acquiring an additional 532 shares during the period. Foresight Group Ltd Liability Partnership purchased a new stake in shares of Genmab A/S during the first quarter worth approximately $954,000. Scientech Research LLC lifted its holdings in shares of Genmab A/S by 209.5% during the first quarter. Scientech Research LLC now owns 34,611 shares of the company’s stock worth $678,000 after purchasing an additional 23,428 shares during the period. Cubist Systematic Strategies LLC lifted its holdings in shares of Genmab A/S by 112.4% during the first quarter. Cubist Systematic Strategies LLC now owns 1,258,143 shares of the company’s stock worth $24,634,000 after purchasing an additional 665,893 shares during the period. Finally, Graham Capital Management L.P. grew its position in Genmab A/S by 28.9% in the 1st quarter. Graham Capital Management L.P. now owns 71,452 shares of the company’s stock valued at $1,399,000 after buying an additional 16,035 shares during the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.